Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects
Status:
Completed
Trial end date:
2006-09-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Europe. The aim of this trial is to demonstrate bio-equivalence
between the marketed activated recombinant human factor VII (NovoSeven®) (CP-rFVIIa) and a
new formulation stable at 25°C (VII25).